Anticoagulation Strategies for Valvular and Non-Valvular Atrial Fibrillation
Definition and Classification
- Valvular AF is defined as AF occurring in the presence of moderate to severe mitral stenosis or mechanical heart valves, and non-valvular AF includes AF in patients with other types of valvular disease, according to the American College of Cardiology 1
- AF in the setting of mitral stenosis increases stroke risk 20 times over that of patients in sinus rhythm, while non-valvular AF increases stroke risk 5 times, as reported by the American College of Cardiology 2
Anticoagulation in Valvular AF
- For patients with AF and mechanical heart valves, warfarin is the only recommended anticoagulant, as stated by the American College of Cardiology 3, 2
- The direct thrombin inhibitor dabigatran is specifically contraindicated in patients with AF and mechanical heart valves, classified as a Class III: Harm recommendation by the American College of Cardiology 3, 2
Anticoagulation in Non-Valvular AF
- For patients with non-valvular AF, stroke risk is assessed using the CHA₂DS₂-VASc score, as recommended by the American College of Cardiology and the American Heart Association 3, 4
- Anticoagulation options for non-valvular AF include warfarin and direct oral anticoagulants (DOACs), with DOACs recommended over warfarin due to similar or better efficacy and lower risk of intracranial bleeding, as stated by the American College of Cardiology 3
Special Considerations
- In patients with non-valvular AF and end-stage chronic kidney disease or on hemodialysis, warfarin is preferred over DOACs, as recommended by the American Heart Association 4
- DOACs are not recommended in patients with AF and end-stage CKD or on dialysis due to lack of evidence, as stated by the American College of Cardiology and the American Heart Association 3, 4
Clinical Implications and Monitoring
- Maximum protection against ischemic stroke in AF is achieved with an INR range of 2.0-3.0, as reported by the European Society of Cardiology 5
- Periodic reevaluation of anticoagulation therapy is recommended to reassess stroke and bleeding risks, as stated by the American College of Cardiology 3